108 related articles for article (PubMed ID: 18789393)
41. Composition and bioactivity of the leaf essential oil of Heteropyxis dehniae from Zimbabwe.
Sibanda S; Chigwada G; Poole M; Gwebu ET; Noletto JA; Schmidt JM; Rea AI; Setzer WN
J Ethnopharmacol; 2004 May; 92(1):107-11. PubMed ID: 15099856
[TBL] [Abstract][Full Text] [Related]
42. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of extracts of Anthocleista djalonensis, Nauclea latifolia and Uvaria afzalii for activity against bacterial isolates from cases of non-gonococcal urethritis.
Okoli AS; Iroegbu CU
J Ethnopharmacol; 2004 May; 92(1):135-44. PubMed ID: 15099860
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection.
Giacometti A; Cirioni O; Kamysz W; Silvestri C; Licci A; Riva A; Łukasiak J; Scalise G
Peptides; 2005 Nov; 26(11):2111-6. PubMed ID: 16269345
[TBL] [Abstract][Full Text] [Related]
45. Screening for antimicrobial activity of ten medicinal plants used in Colombian folkloric medicine: a possible alternative in the treatment of non-nosocomial infections.
Rojas JJ; Ochoa VJ; Ocampo SA; Muñoz JF
BMC Complement Altern Med; 2006 Feb; 6():2. PubMed ID: 16483385
[TBL] [Abstract][Full Text] [Related]
46. [Investigation on the antimicrobial activity of cefoperazone (author's transl)].
Primavesi CA
Immun Infekt; 1981 Jul; 9(4):150-3. PubMed ID: 6456219
[TBL] [Abstract][Full Text] [Related]
47. NTP technical report on the toxicity studies of 2-Chloronitrobenzene (CAS No. 88-73-3) and 4-Chloronitrobenzene (CAS No. 100-00-5) Administered by Inhalation to F344/N Rats and B6C3F1 Mice.
Bucher J
Toxic Rep Ser; 1993 Jul; 33():1-F25. PubMed ID: 12209191
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of antibacterial activity of nitric oxide-releasing polymeric particles against Staphylococcus aureus and Escherichia coli from bovine mastitis.
Cardozo VF; Lancheros CA; Narciso AM; Valereto EC; Kobayashi RK; Seabra AB; Nakazato G
Int J Pharm; 2014 Oct; 473(1-2):20-9. PubMed ID: 24979535
[TBL] [Abstract][Full Text] [Related]
50. Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.
Vanin AF; Pekshev AV; Vagapov AB; Sharapov NA; Lakomkin VL; Abramov AA; Timoshin AA; Kapelko VI
Biophysics (Oxf); 2021; 66(1):155-163. PubMed ID: 33935291
[TBL] [Abstract][Full Text] [Related]
51. Gaseous nitric oxide for the local treatment of bacterial keratitis in mice.
Deichelbohrer M; Wu MF; Seitz B; Wagenpfeil S; Meier C; Bischoff M; Tschernig T
Biomed Rep; 2017 Jan; 6(1):75-78. PubMed ID: 28123711
[TBL] [Abstract][Full Text] [Related]
52. Antimicrobial effects of nitric oxide in murine models of Klebsiella pneumonia.
Wiegand SB; Traeger L; Nguyen HK; Rouillard KR; Fischbach A; Zadek F; Ichinose F; Schoenfisch MH; Carroll RW; Bloch DB; Zapol WM
Redox Biol; 2021 Feb; 39():101826. PubMed ID: 33352464
[TBL] [Abstract][Full Text] [Related]
53. White Light-Activated Antimicrobial Paint using Crystal Violet.
Hwang GB; Allan E; Parkin IP
ACS Appl Mater Interfaces; 2016 Jun; 8(24):15033-9. PubMed ID: 26479680
[TBL] [Abstract][Full Text] [Related]
54. Methemoglobinemia: Toxicity of inhaled nitric oxide therapy.
Taylor MB; Christian KG; Patel N; Churchwell KB
Pediatr Crit Care Med; 2001 Jan; 2(1):99-101. PubMed ID: 12797897
[TBL] [Abstract][Full Text] [Related]
55. The effect of nitric oxide on the growth of Escherichia coli M.
Russell C
Experientia; 1965 Nov; 21(11):625. PubMed ID: 5330186
[No Abstract] [Full Text] [Related]
56. Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms.
Garren MR; Ashcraft M; Qian Y; Douglass M; Brisbois EJ; Handa H
Appl Mater Today; 2021 Mar; 22():100887. PubMed ID: 38620577
[TBL] [Abstract][Full Text] [Related]
57. High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.
Di Fenza R; Shetty NS; Gianni S; Parcha V; Giammatteo V; Safaee Fakhr B; Tornberg D; Wall O; Harbut P; Lai PS; Li JZ; Paganoni S; Cenci S; Mueller AL; Houle TT; Akeju O; Bittner EA; Bose S; Scott LK; Carroll RW; Ichinose F; Hedenstierna M; Arora P; Berra L;
Am J Respir Crit Care Med; 2023 Dec; 208(12):1293-1304. PubMed ID: 37774011
[No Abstract] [Full Text] [Related]
58. Effects of In Vitro Combination of Nitric Oxide Donors and Hypochlorite on Acanthamoeba castellanii Viability.
Park JH; Park CY
Transl Vis Sci Technol; 2023 Sep; 12(9):23. PubMed ID: 37768280
[TBL] [Abstract][Full Text] [Related]
59. The Triple Crown: NO, CO, and H
Oza PP; Kashfi K
Pharmacol Ther; 2023 Sep; 249():108502. PubMed ID: 37517510
[TBL] [Abstract][Full Text] [Related]
60. Development of nitric oxide generators to produce high-dose nitric oxide for inhalation therapy.
Yu B; Wanderley HV; Gianni S; Carroll RW; Ichinose F; Zapol WM; Berra L
Nitric Oxide; 2023 Sep; 138-139():17-25. PubMed ID: 37277062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
